- Home
- UGRO vs MBIO Comparison
UGRO vs MBIO Comparison
Compare UGRO & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- MBIO
- Stock Information
- Founded
- UGRO 2014
- MBIO 2015
- Country
- UGRO United States
- MBIO United States
- Employees
- UGRO N/A
- MBIO N/A
- Industry
- UGRO Industrial Specialties
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- MBIO Health Care
- Exchange
- UGRO Nasdaq
- MBIO Nasdaq
- Market Cap
- UGRO 3.9M
- MBIO 4.7M
- IPO Year
- UGRO N/A
- MBIO N/A
- Fundamental
- Price
- UGRO $0.24
- MBIO $1.17
- Analyst Decision
- UGRO Strong Buy
- MBIO
- Analyst Count
- UGRO 1
- MBIO 0
- Target Price
- UGRO $3.00
- MBIO N/A
- AVG Volume (30 Days)
- UGRO 2.3M
- MBIO 84.3K
- Earning Date
- UGRO 10-30-2025
- MBIO 11-07-2025
- Dividend Yield
- UGRO N/A
- MBIO N/A
- EPS Growth
- UGRO N/A
- MBIO N/A
- EPS
- UGRO N/A
- MBIO N/A
- Revenue
- UGRO $59,985,138.00
- MBIO N/A
- Revenue This Year
- UGRO N/A
- MBIO N/A
- Revenue Next Year
- UGRO $28.40
- MBIO N/A
- P/E Ratio
- UGRO N/A
- MBIO N/A
- Revenue Growth
- UGRO N/A
- MBIO N/A
- 52 Week Low
- UGRO $0.21
- MBIO $0.89
- 52 Week High
- UGRO $1.64
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- UGRO 35.75
- MBIO 35.26
- Support Level
- UGRO $0.21
- MBIO $1.14
- Resistance Level
- UGRO $0.24
- MBIO $1.23
- Average True Range (ATR)
- UGRO 0.04
- MBIO 0.08
- MACD
- UGRO -0.00
- MBIO -0.00
- Stochastic Oscillator
- UGRO 10.66
- MBIO 18.38
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.